Gambro gets $3bn from DaVita for US dialysis clinics
This article was originally published in Clinica
Gambro has agreed to sell its US dialysis clinics to rival DaVita, in return for $3.05bn in cash. The deal will also involve supply and R&D relationship commitments.
You may also be interested in...
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.